



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/783,268
Sheet 1 of 1				Filing Date	February 20, 2004
				First Named Inventor	Andrea Savarino
				Art Unit	1617
				Examiner Name	Samala, J.R.
				Attorney Docket Number	97728.00147

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
/JS/	1	US- 2004/0102431	05/27/2004	Boss	
		US- _____			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
/JS/	1	EP 1 374 867	01/02/2004	Valpharma, S.A.		
/JS/	2	WO 97/08180	03/06/1997	Sommadossi		
		_____				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.	T <sup>2</sup>
/JS/	1	"No drug-drug interaction between nelfinavir or indinavir and mefloquine in HIV-1-infected patients." AIDS (London, England) 1 Dec 2000 Vol. 14, No. 17, Schippers, E. F., et al	
/JS/	2	"Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers." British Journal of Clinical Pharmacology, June 2001 Khaliq, U., et al.	
/JS/	3	"Hydroxychloroquine, hydroxycarbamide, and didanosine as economic treatment for HIV-1." Lancet. 11 May 2002 Vol. 359, no. 9318, Paton, Nicholas I., et al.	
/JS/	4	"Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1." Clinical Therapeutics, 1997 Sep-Oct. vol. 19, no. 5, Sperber, K., et al.	
/JS/	5	Clin. Ther., Sep 1999 Vol. 21, p. 1456-1496, Okereke	

Examiner Signature	/Jagadishwar Samala/ (04/03/2008)	Date Considered	
--------------------	-----------------------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application for to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.